1. Positive Phase IIb results for CimetrA®, a new anti-inflammatory drug. 2. CimetrA® shows strong safety profile, faster COVID-19 recovery. 3. CEO highlights potential for broader inflammatory disease treatment. 4. CannEpil® targets severe epilepsy with innovative formulation.
Positive trial results often lead to increased investor confidence and stock price. Historical examples include successful drug trials boosting company valuations significantly.
The announcement affects investor sentiment directly due to new clinical data.
Immediate positive response expected from the market due to recent trial results.
PERTH, Australia, March 16, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.
CEO Roby Zomer stated: "These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development."
With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil® is making waves in the UK as part of a movement to transform severe epilepsy treatment. This further reinforces Argent BioPharma's commitment to addressing global health challenges.
Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
[email protected]
Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
[email protected]